CLGN · CollPlant Biotechnologies Ltd · Metrics
$4.64
+0.68 (+17.17%)
At close · Nov 12
Return incl. dividend (before tax)
Q3 2024 earnings call transcript
Market Cap
$14.27M
Shares
3.08M
Volume · Nov 12
439.3K
Avg daily vol (49 sessions)
74.48K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
CLGN metrics
56 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$4.64
Market cap
$14.27M
Price action
23 metricsPrice change (1W)
-6.4%
Price change (30D)
+1.3%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
469.6%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
51.0
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
66,883
Relative volume
0.4
Average dollar volume
$256,816
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
3.08M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
38.3×
reciprocal yield 2.6%
P / book
4.1
reciprocal yield 24.2%
FCF yield
-92.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-102.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-09-30
Profitability
9 metricsGross margin
-321.7%
Operating margin
-3,900.9%
Trailing 12 months
Net margin
-3,934.9%
Gross profit (TTM)
−$1.02M
Operating profit (TTM)
−$12.40M
Net income (TTM)
−$12.51M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-3,548.7%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-28.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$318,000
Trailing 12 months
EPS growth YoY
-24.3%
Shares change YoY
+3.4%
Year over year · more shares
Revenue CAGR (3Y)
+99.4%
Revenue CAGR (5Y)
-17.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-424.9%
Return on assets
-173.9%
Debt / equity
—
Current ratio
1.6
EBITDA (TTM)
−$11.56M
Free cash flow (TTM)
−$11.29M
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.56M
Total assets
$7.20M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$11.19M
Capital expenditures (TTM)
$91,000
R&D (TTM)
$6.91M
SG&A (TTM)
—
Stock compensation (TTM)
$609,000
R&D / revenue
2,173.6%
Stock compensation / revenue
191.5%
Ownership (13F)
9 metrics13F filers
15
13F filer change QoQ
-5
Institutional ownership
5.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+9.3%
Holder tenure
15.3
Price vs estimated holder cost
-94.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
1.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—